scholarly journals Effects of Ramadan fasting on moderate to severe chronic kidney disease. A prospective observational study

2017 ◽  
Vol 38 (1) ◽  
pp. 48-52 ◽  
Author(s):  
Amaar Bakhit ◽  
Amr Kurdi ◽  
Junaid Wadera ◽  
Abdulkareem Alsuwaida
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Ramadan Fasting ◽  
Severe Chronic Kidney Disease

scholarly journals A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO)

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Ashraf I. Mikhail ◽  
Staffan Schön ◽  
Sylvia Simon ◽  
Christopher Brown ◽  
Jörgen B. A. Hegbrant ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Iron Deficiency ◽  
Observational Study ◽  
Prospective Observational Study

scholarly journals The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Hitoshi Minakuchi ◽  
Shu Wakino ◽  
Hidenori Urai ◽  
Arata Kurokochi ◽  
Kazuhiro Hasegawa ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Plasma Aldosterone ◽  
Controlled Study ◽  
Ckd Progression ◽  
Mineralocorticoid Receptor Antagonist ◽  
Plasma Aldosterone Concentration ◽  
Ckd Stage

Abstract The progression of chronic kidney disease (CKD) cannot be completely inhibited. We first explored factors contributing to CKD progression in patients with CKD in a prospective observational study. In the next phase, we focused on the effects of aldosterone, conducting a single-blinded placebo-controlled study using the selective mineralocorticoid receptor antagonist (MRA), eplerenone (25 mg/day). We recruited patients with CKD stage 2 and 3 whose plasma aldosterone concentration was above 15 ng/dL based on the prior data of a prospective observational study. In the CKD cohort study (n = 141), baseline plasma aldosterone concentration was identified as an independent contributory factor for the future rate of change in estimated glomerular filtration rate (eGFR). When the cut-off value for aldosterone was set at 14.5 ng/dL, the decline rate was significantly higher in patients with higher plasma aldosterone concentration (− 1.22 ± 0.39 ml/min/1.73 m2/year vs. 0.39 ± 0.40 ml/min/1.73 m2/year, p = 0.0047). In the final intervention study, in the eplerenone group, eGFR dropped at 6 months after the initiation of the study, and thereafter eGFR was maintained until the end of the study. At 24 months and 36 months, eGFR was significantly higher in the eplerenone group than in the placebo group. In conclusion, MRA can be an effective strategy in preventing CKD progression, especially in patients with high plasma aldosterone.

scholarly journals Chronic kidney disease in the emergency centre: A prospective observational study

2018 ◽  
Vol 8 (4) ◽  
pp. 134-139
Author(s):  
Babawale Taslim Bello ◽  
Olalekan Ezekiel Ojo ◽  
Olapeju Funke Oguntunde ◽  
Adedotun Ademola Adegboye
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Observational Study ◽  
Prospective Observational Study

scholarly journals Drug-Related Problems and Associated Factors among Patients Admitted with Chronic Kidney Disease at Jimma University Medical Center, Jimma Zone, Jimma, Southwest Ethiopia: A Hospital-Based Prospective Observational Study

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Aster Wakjira Garedow ◽  
Eshetu Mulisa Bobasa ◽  
Amare Desalegn Wolide ◽  
Fantu Kerga Dibaba ◽  
Fanta Gashe Fufa ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Observational Study ◽  
Associated Factors ◽  
Prospective Observational Study ◽  
Medical Center ◽  
Statistical Significance ◽  
Morbidity And Mortality ◽  
Jimma University

Background. There is an alarming rise of chronic kidney disease prevalence globally associated with significant morbidity and mortality necessitating special attention as one of the major growing public health problems. Medication-related problems are common in hospitalized patients including chronic kidney disease and may lead to increase hospital stay and health care cost and augment the risk of morbidity and mortality. Objective. To determine prevalence of medication-related problems and associated factors among chronic kidney disease patients admitted to Jimma University Medical Center from April to September 2018. Methods. A hospital-based prospective observational study was conducted among 103 chronic kidney disease patients admitted to Jimma University Medical Center from April to September 2018. Data regarding patient characteristics, medications, diagnosis, length of hospitalization, and laboratory results were collected through review of patients’ medical charts. Data were analyzed by using Statistical Package for the Social Sciences (SPSS) version 21.0. Univariate and multivariate logistic regression was utilized to assess the associations between dependent and independent variables. Statistical significance was considered at p value <0.05. Results. Out of 103 chronic kidney disease patients, 81 (78.6%) of patients had MDRs, on average 1.94 ± 0.873 per patient. The rate of overall MRPs was 30.95 per 100 medication orders. The most common MRPs among CKD patients were need additional drug therapy (62 (31%)), nonadherence (40 (20%)), and dose too low (36 (18%)). The most common cause of need additional drug therapy (52 (26%)) was untreated medical conditions; nonadherence (19 (9.5%)) was mostly due to that the patient/caregiver forgets to take/give the medication, and dose too low (29 (14.5%)) was mostly due to that the dose is too low to produce the desired response. Polypharmacy (AOR = 4.695, 95% CI: 1.370–16.091), number of comorbidities (AOR = 3.616, 95% CI: 1.015–1.8741), and stage of CKD (AOR = 3.941, 95% CI: 1.221–12.715) were independent predictors for MRPs. Conclusions. We have demonstrated that medication-related problems are high among chronic kidney disease patients. Marital statuses, stage of CKD, polypharmacy, and comorbidity were independent predictors for MRPs. Interdisciplinary health professionals should work to decrease the high prevalence of MRPs among chronic kidney disease patients.

Sign in / Sign up

Export Citation Format

Share Document